AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
SYNSAM.ST

Synsam AB (publ) (SYNSAM.ST) fair value

Healthcare · Medical Instruments & Supplies · Nasdaq Stockholm · Sweden
kr 55.70+0.54%
Market cap kr 7.8BNext earnings 2026-11-12Updated Oct 22, 2026
Add earnings to calendarGoogle
Our verdict
Trades 19% below our fair value
Price
kr 55.70
Model fair valueConfidence: good
kr 68.76
Model range
kr 31.82 to kr 104
Fair value kr 68.76
Price kr 55.70
5 models fit Synsam AB (publ) and they disagree: 1 of 5 land within 15% of the average.
Two or more of our models back this value.
Discount(i)Bronze59
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
ACCE opinionSynsam AB (publ) (SYNSAM.ST)
Fair value (5 models)
kr 68.76
ACCE price target
kr 64.00
Rating
Undervalued
Horizon
12 months
Fair value published on 22 Oct 2026, 14:04 CEST.
ACCE price target published on 23 Oct 2026, 01:53 CEST.
Rating published on 22 Oct 2026, 14:04 CEST.
Price used: kr 55.70 at the close on 23 Oct 2026, 17:30 CEST.
Models: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
19.0% below
+23.4% to fair value
ACCE score
63
out of 100
P/E
13.9x
forward 13.9x
1-year return
-8.2%
Dividend yield
3.25%

Synsam AB (publ) in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Synsam is a Swedish eyecare retailer and optician chain, selling prescription eyeglasses, contact lenses and sunglasses through its own store network across the Nordics and beyond, alongside its in-house brands. Its edge is vertical integration: running the optical stores, the eye exams and much of the product range under one roof gives it a 74.7% gross margin, which is the kind of figure that usually signals pricing power in a fragmented, service-heavy retail market. Revenue is growing at 11.2%, and with a 23.4% ROE the business is turning its equity into profit efficiently. The stock trades at 13.8 times earnings, which looks undemanding for a company growing at that pace with a 14.2% operating margin. The data we have does not include the near-term catalyst or margin trend, so that is the first thing to pin down before committing research time.

AI-assisted·How I use AIWritten Oct 23, 2026

Next results

Nov 12, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where SYNSAM.ST's valuation models land
Price
kr 55.70
Model fair value
kr 68.76
Model range
kr 31.82 to kr 104
Fair value kr 68.76
Price kr 55.70
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
Dividend discount
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Recent performance

1 week
+3.0%
1 month
+3.9%
3 months
+1.6%
6 months
-4.8%
YTD
-17.5%
1 year
-8.2%

Recommendation history, last 12 months

DateTypeNewPreviousPrice
23 Oct 2026, 01:53 CESTACCE price targetkr 64.00first publicationkr 55.40
22 Oct 2026, 14:04 CESTRatingUndervaluedfirst publicationkr 54.90
22 Oct 2026, 14:04 CESTFair valuekr 68.76first publicationkr 54.90

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

This security trades in SEK. Exchange-rate movements can increase or reduce the result in your own currency.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full SYNSAM.ST page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth76Value69Quality67Momentum40Total63
Valuation
Trailing P/E
13.9x
Forward P/E
13.9x
PEG
0.19
P/B
3.01x
EV / Revenue
1.4x
Book value/sh
kr 17.97
Enterprise value
kr 10.6B
Profitability
ROE
23.4%
FCF yield
12.67%
ROIC
5.8%
Health and risk
Debt / equity
1.63
Dividend yield
3.25%
Beta
0.37

Price

-8.4% · 1Y

Ask anything about SYNSAM.ST

Answered from Synsam AB (publ) fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 13.9x13.9xhigh 134.7x
ROEbetter than 67% of peers
low 1%23%high 40%
Div yieldbetter than 100% of peers
low 0.0%3.3%high 3.3%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
SYNSAM.ST Synsam AB (publ)kr 55.70kr 6919% below13.9x23.4%6763
DYVOX.ST Dynavox Group AB (publ)kr 71.20kr 4559% above27.6x40.4%7651
BONEX.ST Bonesupport Holding AB (publ)kr 332.60--81.5x24.5%8872
ALIF-B.ST AddLife AB (publ)kr 184.20kr 13339% above35.0x11.5%5454
ICUI ICU Medical Inc. Common Stock$166.62$11151% above134.7x1.4%4350
1SXP.DE SCHOTT Pharma AG & Co. KGaA€25.70€1750% above28.6x14.7%6961
ANN.AX Ansell LimitedA$46.27A$4016% above21.6x10.5%6775

Sector report card

Where SYNSAM.ST ranks against its sector peers on each metric.

Computing percentiles…